1 week Ago By Defense World Staff
Orion Portfolio Solutions LLC grew its holdings in shares of iShares U.S. Pharmaceuticals ETF ( NYSEARCA:IHE – Free Report ) by 3.
2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 10,465 shares of the company’s stock after purchasing an additional 321 shares during the quarter. Orion Portfolio Solutions LLC owned approximately 0.
10% of iShares U.S. Pharmaceuticals ETF worth $688,000 at the end of the most recent reporting period.
A number of other hedge funds also recently made changes to their positions in the business. JPMorgan Chase & Co. increased its holdings in iShares U.
S. Pharmaceuticals ETF by 2,176.8% during the fourth quarter.
JPMorgan Chase & Co. now owns 188,567 shares of the company’s stock worth $12,393,000 after buying an additional 180,285 shares during the last quarter. Woodmont Investment Counsel LLC bought a new stake in shares of iShares U.
S. Pharmaceuticals ETF in the 4th quarter worth approximately $366,000. Runnymede Capital Advisors Inc.
purchased a new position in iShares U.S. Pharmaceuticals ETF in the fourth quarter valued at approximately $164,000.
Thrivent Financial for Lutherans grew its holdings in iShares U.S. Pharmaceuticals ETF by 4.
3% during the fourth quarter. Thrivent Financial for Lutherans now owns 33,916 shares of the company’s stock valued at $2,229,000 after purchasing an additional 1,407 shares during the period. Finally, Axxcess Wealth Management LLC increased its position in iShares U.
S. Pharmaceuticals ETF by 47.3% in the fourth quarter.
Axxcess Wealth Management LLC now owns 5,001 shares of the company’s stock worth $329,000 after buying an additional 1,607 shares during the last quarter. iShares U.S.
Pharmaceuticals ETF Price Performance Shares of NYSEARCA IHE opened at $63.43 on Monday. The business’s fifty day moving average price is $70.
18 and its 200-day moving average price is $69.09. iShares U.
S. Pharmaceuticals ETF has a one year low of $62.68 and a one year high of $73.
28. The stock has a market capitalization of $558.18 million, a PE ratio of 25.
04 and a beta of 0.63. iShares U.
S. Pharmaceuticals ETF Profile iShares U.S.
Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund.
The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index).
The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins. Featured Stories Five stocks we like better than iShares U.S.
Pharmaceuticals ETF Consumer Discretionary Stocks Explained Newsmax’s IPO Whiplash: Meme Stock Hype or Growth Potential? 5 Top Rated Dividend Stocks to Consider Disney 2025 Shareholders: Major Updates for Investors Stock Average Calculator Advance Auto Parts Stock: A Classic Rebound Play in the Making Want to see what other hedge funds are holding IHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares U.S.
Pharmaceuticals ETF ( NYSEARCA:IHE – Free Report ). Receive News & Ratings for iShares U.S.
Pharmaceuticals ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares U.S. Pharmaceuticals ETF and related companies with MarketBeat.
com's FREE daily email newsletter ..
